According to the company, Mario Polywka, COO, and Klaus Maleck, CFO, will jointly lead the organization until a permanent successor is announced.
Flemming Ornskov, chairman of the supervisory board of Evotec, said: “During his 11-year tenure at Evotec, Joern Aldag played a pivotal role in the transformation of Evotec from a technology provider to an integrated, CNS-focused biopharmaceutical company. Today the company has a very strong financial position and a deep preclinical and clinical pipeline of CNS drug candidates that provide a strong basis for future success.
“On behalf of the Evotec supervisory board, I would like to thank Joern Aldag for his effective and very successful leadership of the company and we wish him ongoing success for his future endeavors.”